secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eiger BioPharmaceuticals, Inc. (—)
CIK:        0001305253
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0001193125-24-086059
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Eiger BioPharmaceuticals files Chapter 11, receives Nasdaq delisting notice; shares to trade OTC
--------------------------------------------------------------------------------

- Filed Chapter 11 petitions on April 1, 2024; Nasdaq issued delisting notice on April 2.
- Company will not appeal; trading suspended on Nasdaq effective April 11, 2024.
- Common stock expected to trade OTC under symbol EIGRQ starting April 11, 2024.
- Director Jeffrey S. Glenn resigned April 1, 2024, citing no disagreement with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524086059/0001193125-24-086059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524086059/d819347d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-086059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer